Edinburgh BioQuarter
Edinburgh BioQuarter
47 Little France Crescent
Edinburgh
EH16 4TJ
ABOUT
Edinburgh bioQuarter is being developed as a leading life sciences location which works in a variety of ways to drive innovation and deliver healthcare, research, and economic benefits.
Situated three miles south of Edinburgh City Centre, the bioQuarter site comprises two major hospitals, several leading University of Edinburgh research institutes, and accommodation for young, growing, and established companies. This innovative environment ensures that industry, academia, and the NHS can work and collaborate side-by-side and develop into the future.
 Unique Selling Points
Edinburgh bioQuarter represents an opportunity for companies to co-locate and engage with world-leading medical and biomedical research. It includes a major teaching hospital (the Royal Infirmary of Edinburgh), the University of Edinburgh Medical Faculty, and the Centre for Regenerative Medicine, which is home to a globally-recognised regenerative medicine research team and state of the art research facilities. In addition, the site houses the Queen’s Medical Research Institute and the Anne Rowling Regenerative Neurology Clinic. The site also provides superb facilities for commercial companies and significant and unique opportunities for academic, clinical and industrial collaboration.
In 2018, the existing 870-bed Royal Infirmary of Edinburgh will be joined by the 300-bed Royal Hospital for Children and Young People and Department of Clinical Neurosciences. In total, there will be some 1,200 hospital beds, 2,000 researchers, and 6,000 clinical and support staff at the bioQuarter site, making it one of the most significant concentrations of medical assets and scientific talent in Europe.
NINE bioQuarter, which was opened by HRH the Princess Royal in June 2012, has rapidly established itself as the centre for commercial activity at bioQuarter. NINE is currently home to over 20 commercial tenants ranging from spin-out companies to established global life science businesses, and also houses the Farr Institute, Scotland, part of a UK-wide research collaboration of major universities which aims to position the UK as a world leader in health informatics research.
Business Support
Companies locating at Edinburgh bioQuarter enjoy access to a range of public sector funding and support Scottish Enterprise and Scottish Development International (SDI) can offer tailored business support for companies locating in the bioQuarter. SDI provides a single point of contact for inward investments, ensuring a seamless passage into Scotland, and helps businesses in sourcing financial assistance or developing projects. A wide range of funding options, both public and private is potentially available to tenants. These options include innovative support schemes for research and development, and for training.
Facilities and Services
In addition to the existing organisation and institutes already located at Edinburgh bioQuarter, the 100-acre site could provide over 1 million sq ft of additional academic and commercial research facilities.
Surrounding area
Edinburgh, the capital city of Scotland, enjoys the UK’s strongest city economy and transport mix outside London, alongside excellent communications networks, property investment opportunities, a rich creative environment and an excellent quality of life.
Future Plans
Adding to the exciting development of the new Royal Hospital for Children and Young People and Department of Clinical Neurosciences, is the construction at site of the University of Edinburgh’s Centre for Tissue Regeneration and Repair. The new Centre will expand the work of the existing Centre for Regenerative Medicine, creating the combined Institute for Regeneration and Repair. This will accommodate a further 250 researchers at site and enable translation of stem cell and regenerative medicine research into clinical models and treatments. Construction will start in 2017.
For further information about BioQuarter go to https://edinburghbioquarter.com/
NEWS
Cell and Gene Therapy Catapult Opens New Laboratories and Offices in Edinburgh BioQuarter
New laboratory space and expert teams will help accelerate the development of potentially life-saving cell therapies The facility enhances Edinburgh’s role as a hub for cell therapies; with the aim to attract further international companies to the area The Cell and...
RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole
RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole. The additional space will include fully fitted...
Pandemic Science Hub to develop better drugs to fight lung disease
A new multi-million pound research programme to develop treatments for lung infections such as Covid-19 and future pandemics has been announced at the University of Edinburgh with support from a significant donation by Baillie Gifford. The Baillie Gifford Pandemic...
GHO Capital invests in RoslinCT, a leading cell therapy CDMO
RoslinCT, a leading Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, announces investment from Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare....
BioQuarter opens bidding for private sector partner for £1bn transformation project
Edinburgh BioQuarter has formally launched its public procurement process for a private sector partner. The opportunity to create a £1billion (estimated gross development value) health innovation district which will create jobs, homes, and a community for thousands of...
Interested in joining UKSPA?
Gain exclusive access to members only resources, research papers, statistics and data – as well as discounted or even free entry to the conferences and events we hold through the year.